CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenues
Sanofi collaboration revenue	$ 84,446	$ 84,941	$ 169,775	$ 153,612
Other collaboration revenue	11,123	13,635	23,604	26,722
Technology licensing	5,228	10,037	13,073	20,075
Net product sales	5,039	5,197	9,466	15,049
Contract research and other	1,974	2,076	4,096	3,962
Total revenues	107,810	115,886	220,014	219,420
Expenses
Research and development	143,149	124,526	272,541	241,997
Selling, general, and administrative	24,585	14,679	47,996	28,902
Cost of goods sold	395	405	777	1,122
Total expenses	168,129	139,610	321,314	272,021
Loss from operations	(60,319)	(23,724)	(101,300)	(52,601)
Other income (expense)
Investment income	998	592	2,035	1,031
Interest expense	(4,047)	(2,342)	(7,766)	(4,426)
Total other income (expense)	(3,049)	(1,750)	(5,731)	(3,395)
Net loss before income tax benefit	(63,368)	(25,474)	(107,031)	(55,996)
Income tax benefit	(863)	0	(1,079)	0
Net loss	$ (62,505)	$ (25,474)	$ (105,952)	$ (55,996)
Net loss per share, basic and diluted	$ (0.69)	$ (0.31)	$ (1.18)	$ (0.69)
Weighted average shares outstanding, basic and diluted	90,436	81,492	89,799	81,330